Hikma Pharmaceuticals PLCHIK.L
What Hikma Pharmaceuticals PLC does.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.6B | $2.5B | $2.9B | $3.1B | $3.3B |
| Net income | $431.0M | $421.0M | $188.0M | $190.0M | $359.0M | $402.0M |
| Free cash flow | $292.0M | $493.0M | $392.0M | $439.0M | $399.0M | $239.0M |
More on HIK.L.
- Hikma Pharmaceuticals PLC summary
- Hikma Pharmaceuticals PLC financial statements
- Hikma Pharmaceuticals PLC key metrics
- Hikma Pharmaceuticals PLC health scores
- Hikma Pharmaceuticals PLC valuation
- Hikma Pharmaceuticals PLC dividends
- Hikma Pharmaceuticals PLC peers
- Hikma Pharmaceuticals PLC annual reports
Figures from Hikma Pharmaceuticals PLC's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.